SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-009654
Filing Date
2022-05-12
Accepted
2022-05-12 16:07:46
Documents
16
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tals-20220512.htm   iXBRL 8-K 56200
2 EX-99.1 tals-ex99_1.htm EX-99.1 110836
3 GRAPHIC img186005553_0.jpg GRAPHIC 3366
4 GRAPHIC img186005553_1.jpg GRAPHIC 3366
5 GRAPHIC img186005553_2.jpg GRAPHIC 3366
  Complete submission text file 0000950170-22-009654.txt   308235

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tals-20220512_lab.xml EX-101.LAB 13438
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tals-20220512_pre.xml EX-101.PRE 9930
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tals-20220512.xsd EX-101.SCH 2486
10 EXTRACTED XBRL INSTANCE DOCUMENT tals-20220512_htm.xml XML 4705
Mailing Address 93 WORCESTER STREET WELLESLEY MA 02481
Business Address 570 PRESTON ST. SUITE 400 LOUISVILLE KY 40202 502-398-9250
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 22917822
SIC: 2836 Biological Products, (No Diagnostic Substances)